Immunome IMNM Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -5,947.9%-3,954pp | -3,228.8%+154pp | -2,419.9%+714pp | -1,784.1%+734pp | -1,994.3%-123pp | |
| Net margin | -5,593.8%-3,719pp | -3,060%+180pp | -2,301.3%+713pp | -1,687.1%+748pp | -1,875.2%-45.8pp | |
| EBITDA margin | -5,886.7%-3,911pp | -3,193.3%+172pp | -2,396.3%+726pp | -1,767.4%+742pp | -1,975.8%-108pp | |
| Free cash flow margin | -5,118.9%-3,644pp | -2,890.1%-1,585pp | -1,982%-1,068pp | -1,476.8%— | -1,475.2%— | |
| Returns | ||||||
| Return on equity | -50.1%+19.1pp | -52.1%+143pp | -93%+183pp | -81.2%+118pp | -69.2%+85.8pp | |
| Return on assets | -46.7%+15.3pp | -46%+105pp | -80.1%+94.4pp | -71.7%+83.9pp | -61.9%+64.2pp | |
| Return on invested capital | -746.6%-135pp | —— | —— | -203.4%— | -611.6%— | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 21.7×+11.2× | 14.7×+10.6× | 8.9×+2.7× | 12.1×+5.0× | 10.5×+0.3× | |
| Quick ratio | 21.7×+11.2× | 14.7×+10.6× | 8.9×+2.7× | 12.1×+5.0× | 10.5×+0.3× | |
| Cash ratio | 21.3×+12.9× | 14.5×+11.9× | 8.7×+4.7× | 6.3×+2.1× | 8.4×-0.4× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $5.20+34.5% | $7.26+135% | $3.00-15.9% | $3.09-26.9% | $3.87-30.2% | |
| Valuation | ||||||
| Market capitalization | $2.47B+323% | $2.37B+258% | $1.02B+16.1% | $776.15M+7.0% | $585.18M-60.0% | |
| Enterprise value | $1.9B+470% | $1.72B+228% | $750.67M+3.5% | $636.42M+13.0% | $332.33M-72.2% | |
| Price / sales | 616.2×+563× | 341.4×+268× | 105.3×+18.6× | 61.7×-5.6× | 53.5×-62.0× | |
| Price / book | 4.2×+2.3× | 3.7×+0.1× | 3.9×-0.2× | 2.9×0.0× | 1.9×-3.2× | |
| EV / sales | 472×+442× | 247.9×+190× | 77.6×+6.0× | 50.6×-1.7× | 30.4×-63.9× | |
| Free cash flow yield | -8.3%+19.3pp | -8.5%+9.3pp | -18.8%-8.3pp | -24%— | -27.6%— | |
| Earnings yield | -9.1%+26.0pp | -9%+35.2pp | -21.9%+12.9pp | -27.4%+8.8pp | -35.1%-19.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Immunome's ratios come from?
- Every ratio is computed from Immunome's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.